Neogap’s patented technology behind groundbreaking MS research
Antibodies against Epstein-Barr virus (EBV), a common virus that most people acquire early in life, are linked to multiple sclerosis (MS). This is shown in a study from the Karolinska Institutet, where technology from the biotech company Neogap Therapeutics has been used to map immune cells reactive to EBV and autoantigens related to MS.